These findings have provided the rationale for clinical studies aiming at expanding Tregs in vitro, or increasing Treg numbers and fitness in vivo by IL-2 administration, for the treatment of autoimmune diseases [13], [14], [15]. This evidence concerns the gene IL2 and autoimmune disease.